Cancer Channel
Topics
Medications
Quicklinks
Related Channels

Bosutinib

People who have a certain type of leukemia may benefit from taking bosutinib. By interrupting the production of abnormal blood cells, this prescription medication can help slow down the progression of the cancer. It comes as a tablet that is taken once daily. Side effects are common and may include nausea, vomiting, and abdominal (stomach) pain.

What Is Bosutinib?

Bosutinib (Bosulif®) is a prescription medication approved for the treatment of leukemia, a cancer of the blood cells and bone marrow. It is specifically approved to treat a type of leukemia called Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML). Bosutinib is reserved for use in people who no longer benefit from or cannot tolerate other types of treatment.
 
(Click What Is Bosutinib Used For? for more information on this topic, including possible off-label uses.)
 

Are There Side Effects?

Just like any medicine, bosutinib can cause side effects. Although not everyone who takes the drug will have problems, most people will experience some type of bosutinib side effect during treatment. Talk with your healthcare provider about ways to prevent or lessen reactions to this drug. 
 
Common side effects of bosutinib include but are not limited to:
 
  • Diarrhea
  • Nausea
  • Vomiting
  • Low platelet levels, which could cause abnormal bleeding or bruising
  • Abdominal (stomach) pain.
 
(Click Bosutinib Side Effects to learn more, including potentially serious side effects you should report immediately to your healthcare provider.)
 
7 Natural Ways to Reduce Your Cancer Pain

Bosutinib Drug Information

Referring Pages:
Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.